From the ongoing revision of the EU pharmaceutical legislation package and addressing critical supply issues to the impact of the recent Medical Device Regulation transition period extension, the challenges in EU healthcare and pharmaceutical policy are ever-evolving.
In April 2023, the European Commission published new legislative proposals to revise the EU’s long-standing pharmaceutical legislation and ensure it can meet the challenges of the 21st century. The revision will redefine the regulatory framework for medicines and have a significant impact on the global innovation ecosystem.
Held annually since 2004, the TOPRA Symposium is Europe’s premier conference for healthcare regulatory affairs. With dedicated programme streams for human medicines, medical devices and IVDs, and veterinary medicines, the Symposium is the must-attend event in the regulatory affairs calendar.
The World Orphan Drug Congress is the largest and most established orphan drugs & rare diseases meeting of its kind across the globe.
This panel will discuss what the legislation brings, its potential impact on businesses and what needs to be done to change the legislation in its journey to a final version, that it works for both, the biotech ecosystem, maintaining innovation pipelines, and patients.
Hybrid Event | Invitation Only EuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific, regulatory, and policy issues between patient […]
The IHI Call Days are your one-stop-shop to get detailed information on our calls for proposals and network with potential partners for your consortium.
Event agenda 12:00: Registration opens 12:30: Panel starts 13:45: Panel close and networking lunch 15:00: Close Confirmed Speakers Tomislav Sokol MEPMember SANT Committee, European Parliament Hilde […]
Join our very own Healthcare Policy Senior Manager, Adrien Samson in Madrid where he will be speaking in the panel "Innovation, Funding and Access to Orphan Drugs: Challenges and Opportunities" between 12:15 and 13:00.
Join us on 7 March to discuss the impact of revision of the EU’s General Pharmaceutical Legislation (GPL) on Europe’s innovation ecosystem and biotechnology companies.
Join us on 7 March to discuss the impact of revision of the EU’s General Pharmaceutical Legislation (GPL) on Europe’s innovation ecosystem and biotechnology companies.
Against the backdrop of the Belgian EU Council Presidency, the Rare Diseases Forum 2024 brings together senior leaders from across patient organisations, industry and policy to […]
